The trajectory of the erectile dysfunction drug presents a complex picture for shareholders. While the initial launch generated substantial returns, the lapse of its exclusive rights opened the avenue to off-brand https://cheapbookmarking.com/story21530047/sildenafil-and-big-pharma-a-volatile-bet